A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

Among patients who received four-drug consolidation therapy, 84% had measurable residual disease (MRD)-negative status before ...

The guideline recommendations advise universal use of hydroxychloroquine, minimizing steroids, and earlier introduction of ...

The 12-year-old company had been collaborating with British pharmaceutical giant GlaxoSmithKline on an immuno-oncology drug ...

A new American Diabetes Association consensus statement provides guidance on screening, diagnosing, and managing metabolic ...

India’s pharmaceutical market grew 7.2% in May 2025, driven by price hikes and new launches, with chronic therapies and smaller segments like urology and antineoplastics seeing strong double-digit ...

The strong financials and positive sentiment may have contributed to GlaxoSmithKline Pharmaceutical's stock reaching a new 52 ...

Its 1.02% rally was driven by a surprising 50bps repo rate cut from RBI. This drove a broadbased rally as interest sensitives ...

With GlaxoSmithKline Pharmaceuticals' shares trading at Rs 3187.00, the stock has shown a positive movement, driven by ...

The University of Waterloo’s School of Pharmacy announced Friday a partnership with multinational biopharma company ...

A return of a former CEO and questions about its Medicare Advantage pricing dominate the outlook for this formerly ...

India's GlaxoSmithKline Pharmaceuticals reported a higher fourth-quarter profit on Tuesday, led by steady demand for its generic drugs.